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locoregional right-sided breast cancer treatment in this 
study, a slightly lower risk of pneumonitis and secondary lung 
cancer (in ever-smoking patients) can be expected. In 
addition, we estimate that for 10-25% of the patients the 
heart dose will also be reduced. We therefore suggest to also 
apply breath-hold for locoregional irradiation (with and 
without IMN) of patients with right-sided breast cancer. 
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Purpose or Objective: A large recent study( 1) has shown 
that in patients with early-stage breast cancer, irradiation of 
the regional (internal mammary and medial supraclavicular) 
nodes improves disease-free and distant disease-free 
survival, while breast-cancer mortality is reduced. However, 
internal mammary nodes (IMN) are usually delineated using 
anatomical landmarks, e.g. using the ESTRO delineation atlas 
(2), since the nodes are not visible on CT. We studied the 
impact of SPECT-CT lymphoscintigraphy on the localisation of 
IMN and on the subsequent treatment planning and dose 
distribution.  
 
Material and Methods: For 10 breast cancer patients (5 right, 
5 left), SPECT-CT lymphoscintigraphy of the IMN was 
performed. Using the Eclipse TPS (Varian), the SPECT-CT and 
planning CT images were co-registered. The 70% of the 
maximum uptake value was used to contour the IMN on 
SPECT-CT images. Using the ESTRO atlas, the IMN were also 
contoured on the planning CT images. The localisation of IMN 
based on the SPECT-CT images and based on the ESTRO atlas 
were compared, as well as treatment plans based on the two 
contouring methods.  
 
Results: For 2 patients, no drainage to the IMN was visible. 
For 6 out of the remaining 8 patients, the caudal border of 
the IMN based on SPECT-CT was situated at the second 
intercostal (IC) space, whereas the ESTRO atlas prescribes to 
include the third or fourth IC space depending of the position 
of the tumour in the breast. In the lateral direction, the 
lymph nodes mostly follow the veins, but for one patient, the 
position on SPECT-CT was more medial (and missed by the 
ESTRO atlas) and for one more lateral. On treatment 
planning, for one patient only 50% of the IMN seen on SPECT-
CT would have been covered following contouring using the 
ESTRO atlas. The mean heart dose (MHD) increased by 0.8 Gy 
for one patient and decreased by 1.0 Gy for one patient and 
the mean lung dose (MLD) decreased by 2 Gy for one of the 
patients following SPECT-CT based delineation. For the other 
patients, the differences in MHD and MLD were less than 0.5 
Gy.  
 
Conclusion: Delineation of the IMN using SPECT-CT 
lymphoscintigraphy is easier and less user dependent than 
using the delineation atlas. In general, the agreement 
between atlas and SPECT-CT based delineation is good. 
However, the caudal border of the IMN was overestimated in 
6 out of 8 patients. Differences in the medial border were 
also observed, resulting in underdosage of the IMN in 1 and 
overdose to lung and heart in 1 other patient. SPECT-CT 
lymphoscintigraphy might be applied for patients with a high 
heart dose, to investigate whether the caudal and medial 
border of the IMN may be reduced.  
(1) Poortmans PM, et al. Internal Mammary and Medial 
Supraclavicular Irradiation in Breast Cancer. N Engl J Med 
2015; 373:317-327.  
(2) Offersen BV, et al. ESTRO consensus guideline on target 
volume delineation for elective radiation therapy of early 
stage breast cancer. Radiother Oncol 2015 Jan;114(1):3-10. 
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Purpose or Objective: Increased biological information on 
individual tumors can be obtained with 21-gene recurrence 
score (RS) testing, which has revolutionized receipt of 
chemotherapy. Similar biological drivers of outcomes may be 
useful in determining who might benefit from post-
mastectomy radiation, as is being investigated in the 
SUPREMO and other trials. This study aimed to determine 
who was getting post-mastectomy radiation in a T2N0 cohort, 
as well as whether the recurrence test score affected 
radiation radiation therapy receipt. 
 
Material and Methods: The National Cancer Data Base 
captures about 75% of all US cancer patients and was queried 
for breast cancer patients from 2004-2012. 5302 T2N0 post-
mastectomy patients were identified. Multivariate logistic 
regression analysis was used to estimate the covariates 
associated with test utilization and impact on radiation 
therapy decisions (see table). Z-test was used to measure the 
difference between radiation receipt for those who had the 
test and those who did not. 
 
Results: Post-mastectomy radiation was delivered for 431 
patients (8.1%) of the 5302 included patients. Multivariate 
statistics were used to investigate potential radiation drivers 
including age, race, insurance status, grade, recurrence 
score, and presence of cells in the nodes on 
immunohistochemical staining (N0i+ versus N0i-). The 
strongest association with receipt of radiation therapy was 
N0i+ status (p<.002) versus N0. Age, race, insurance status, 
grade, and actual recurrence score did not predict for receipt 
of post-mastectomy radiation therapy. 
 
Conclusion: As expected, radiation was used in a minority of 
this cohort. Presence of cells in a lymph node was the largest 
driver, even though the disease burden in the nodes was very 
low to be T2N0i+. In patients where the recurrence score was 
ordered, it also predicted for non-receipt of radiation 
therapy as a rationale de-escalation of care. The biggest 
driver of radiation was Noi+ status, where at least a small 
number of cells reached the lymph nodes and radiation might 
be expected to have an impact. Interestingly, increasing 
recurrence score reflecting aggressive biology and poorer 
outcomes did not drive PMRT receipt in this population. In 
the future, use of the recurrence score may help select 
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Purpose or Objective: Regional radiotherapy (RT) is 
replacing axillary lymph node (LN) dissection in breast-cancer 
patients with tumor-positive sentinel node(s) (SNs). In 
regional RT, only part of the LNs can be visualized using 
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computed tomography (CT); consequently, LN levels are 
delineated according to vessels and muscular boundaries. 
Magnetic resonance imaging (MRI) allows high resolution and 
high contrast images for explicit LN visualization in supine RT 
position. The purpose of the study was to assess effects of 
sentinel-node-biopsy (SNB) on MRI detection rate and on 
patient endurance, and relate MRI detection rate to CT. 
 
Material and Methods: Currently, 8 of in total 25 female 
early-stage breast-cancer patients (cT1-3, N0) have been 
enrolled, scheduled for SNB and breast-conserving surgery 
(BCS). Additional to standard postoperative CT for RT 
planning, all patients were scanned on 1.5 T MRI, before and 
after BCS. CT and MRI were performed in supine RT position, 
with both arms abducted and supported. MRI comprised two 
T1-weighted (T1w) spoiled gradient echo techniques, two 
T2w fast spin echo methods, and diffusion-weighted MRI, all 
covering the axillary and periclavicular areas using posterior 
and anterior 16-array coils. MRI acquisition was limited to 20 
minutes per session. Patient endurance to undergo MRI was 
monitored qualitatively. A radiation oncologist delineated LN 
levels on both MRI and CT (levels I-IV, interpectoral) 
according to ESTRO contouring guidelines. By inspection of all 
MRI scans acquired in one session, individual LNs were 
delineated. The detection rate, i.e. number of LNs 
identified, was determined for CT and for each MRI session. 
The pre- and postoperative MRI detection rates were 
compared to assess influence of SNB, and also compared to 
CT. For each LN, the corresponding LN level was denoted. 
 
Results: The number of LNs on postoperative MRI exactly 
matched the preoperative number for all 8 patients (range: 
19 – 42), when adding the excised SNs. All SNs were 
retrospectively identified in level I on preoperative MRI. In 7 
out of 8 patients, spatial correspondence of all other LNs 
between MRI sessions was established. In one patient, a post-
SNB seroma was visible, but detection number was 
unaffected. The majority of LNs were located in the LN 
levels, while up to 7 were found outside (up to 6 mm). LN 
detection on CT (7 – 21 LNs) was much lower than MRI. 





Conclusion: MRI after SNB is able to identify the exact 
numbers of LNs as found on pre-SNB MRI. CT detection rate is 
much lower than MRI. SNB does not affect patient endurance. 
All excised SNs were identified on preoperative MRI. Some 
LNs were located just outside the LN levels. MRI in RT 
planning may lead to better target definition compared to 
CT. In future studies, we will study personalized RT using MRI 
guidance, possibly leading to reduced target volume. Based 
on current patient inclusion rate, updated results on all 25 
patients are expected soon. 
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Purpose or Objective: 
Background: Partial breast irradiation (PBI) is an attractive 
treatment option for well selected women undergoing breast 
conserving therapy for early stage breast cancer. In properly 
selected women, outcomes following PBI are comparable to 
conventional whole breast radiation. The CyberKnife linear 
accelerator may offer meaningful technical improvements to 
existing PBI techniques. We report our experience with 
CyberKnife stereotactic accelerated partial breast irradiation 
(CK-SAPBI).  
 
Material and Methods: Between 11/2008 and 09/2015, CK-
SAPBI was attempted on 21 patients with early stage breast 
cancer. Four to six gold fiducials were implanted around the 
lumpectomy cavity prior to treatment. Fiducials were tracked 
in real-time using the CK Synchrony tracking system. Prior to 
2014, the clinical target volume (CTV) was defined on 
contrast enhanced CT scans using surgical clips and the 
obvious post-operative cavity. A 5 mm uniform expansion was 
added to generate the planning treatment volume (PTV). 
Starting in 2014, the CTV was defined on contrast enhanced 
CT scans as the lumpectomy cavity plus a 10 mm uniform 
expansion confined to the breast tissue. A 3-5 mm uniform 
expansion was added to generate the PTV. All patients 
received 30 Gy in five fractions delivered to the PTV. 
Dosimetry was assessed per institutional protocol, the 
National Surgical Adjuvant Breast and Bowel Project B-39 
